The statistically significant differences in the reporting of specific side effects (e.g., abnormal lab findings, gastrointestinal, and hepatobiliary effects) indicate that a users understanding of semaglutides risk profile is not based solely on clinical evidence, but is heavily mediated by the platform they use (6, 46)
Do not double the dose to "catch up." Mistake 4: Comparing milligrams across peptides A user on semaglutide 2.4 mg who switches to tirzepatide should not start at 2.5 mg thinking it is "about the same." While 2.5 mg happens to be the tirzepatide starting dose, the reasoning should be based on escalation protocol, not milligram matching
Cell immune deconvolution results shown in Supplementary Fig
To address this residue numbering issue, a set of three numbering schemes are summarized as below: the amino acid residue numbering is from 7 to 37, the same as Figure 1 for the experimental structure determined by X-ray diffraction of the semaglutide backbone in complex with GLP-1R ECD (PDB ID: 4ZGM [29])